Sun Pharma Focuses On Expanding In The Chinese Generic Market
Sun Pharma continues to build its global specialty business with an increasing focus on China and Japan. As it revealed first-quarter results, the company announced a licensing deal with CMS and a new leader for its operations in China.
You may also be interested in...
India's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize on the UK firm’s strong position in this market.
Aurobindo has formed a new joint venture with a Chinese partner to supply products for the world’s second-largest pharmaceutical market, as Beijing’s drug procurement reforms gather pace.
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.